| Pathogenic Gαo Mutants Drive Dominant GPCR Coupling in GNAO1 Encephalopathies | The FASEB journal |  | | 2026 | 47 | 85 |
|
| Loss of the conserved switch III region in a G protein leads to severe pediatric encephalopathy | Science signaling |  | | 2025 | 22 | 0 |
|
| Clinical-molecular profiling of atypical GNAO1 patients : Novel pathogenic variants, unusual manifestations, and severe molecular dysfunction | Genes & diseases | | | 2025 | 41 | 30 |
|
| Atypical GNAO1 variants in severe childhood speech disorders: clinical, genetic, and molecular insights | Molecular autism | | | 2025 | 17 | 26 |
|
| Zinc for GNAO1 encephalopathy : preclinical profiling and a clinical case | Med | | | 2024 | 135 | 348 |
|
| Clinical and Molecular Profiling in GNAO1 Permits Phenotype–Genotype Correlation | Movement disorders | | | 2024 | 103 | 221 |
|
| GNAO1 Mutations Affecting the N‐Terminal α‐Helix of Gαo Lead to Parkinsonism | Movement disorders | | | 2024 | 119 | 265 |
|
| Personalized Drug Discoveries for Patients with GNAO1 Encephalopathies | | | | 2023 | 342 | 478 |
|
| Clinical Cases and the Molecular Profiling of a Novel Childhood Encephalopathy-Causing GNAO1 Mutation P170R | Cells | | | 2023 | 120 | 92 |
|
| In-depth molecular profiling of an intronic GNAO1 mutant as the basis for personalized high-throughput drug screening | Med | | | 2023 | 139 | 1 |
|
| Pediatric GNAO1 encephalopathies: from molecular etiology of the disease to drug discovery | Neural Regeneration Research | | | 2023 | 111 | 194 |
|
| Restoration of the GTPase activity and cellular interactions of Gαo mutants by Zn2+ in GNAO1 encephalopathy models | Science advances | | | 2022 | 212 | 201 |
|
| Unlocking the Wnt pathway : therapeutic potential of selective targeting FZD7 in cancer | Drug discovery today | | | 2021 | 550 | 538 |
|
